Your session is about to expire
What is Irinotecan Hydrochloride
IrinotecanThe Generic name of this drug
Treatment SummaryIrinotecan is a cancer medication that works by blocking an enzyme called topoisomerase I, which is needed for cancer cells to grow. It is primarily used to treat colorectal cancer, but it was also approved in 2015 to treat advanced pancreatic cancer. It is derived from camptothecin and works by binding to topoisomerase I-DNA complex, leading to double-strand DNA breakage and cell death.
Camptosaris the brand name
Irinotecan Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Camptosar
Irinotecan
1996
56
Approved as Treatment by the FDA
Irinotecan, commonly known as Camptosar, is approved by the FDA for 2 uses which include Neoplasm Metastasis and Metastatic Colorectal Carcinoma .Neoplasm Metastasis
Used to treat refractory, metastatic Pancreatic adenocarcinoma in combination with Fluorouracil
Metastatic Colorectal Carcinoma
Used to treat Metastatic Colorectal Carcinoma in combination with Fluorouracil
Effectiveness
How Irinotecan Hydrochloride Affects PatientsIrinotecan is a drug used to treat colorectal cancer. It works by blocking an enzyme called topoisomerase I which helps manage how the DNA in cells is wound up and relaxed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent it from repairing itself. This prevents the DNA from being able to do key processes like replicating, recombining, and repairing. It is most effective during the S-phase of the cell cycle, when the DNA is actively replicating. The exact contribution of SN-38 to Irinot
How Irinotecan Hydrochloride works in the bodyIrinotecan works by blocking topoisomerase I, an enzyme that helps to repair DNA. When topoisomerase I is blocked, the DNA strand is unable to be repaired, leading to programmed cell death.
When to interrupt dosage
The measure of Irinotecan Hydrochloride is contingent upon the determined malady, including Ovarian Cancer, Pancreatic Cancer and Stomach Cancer. The dosage may differ, due to the method of delivery (e.g. Injection, solution or Injection) detailed in the table beneath.Condition
Dosage
Administration
Neoplasm Metastasis
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Ovarian Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Sarcoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Rhabdomyosarcomas
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Non-Small Cell Lung Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Glioblastoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Stomach Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Colorectal Carcinoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Metastatic Colorectal Carcinoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Small Cell Lung Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Pancreatic Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Warnings
There are 20 known major drug interactions with Irinotecan Hydrochloride.Common Irinotecan Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Aldosterone.
Irinotecan Hydrochloride Toxicity & Overdose RiskTaking too much of a certain drug can lead to stomach issues such as feeling sick, throwing up, stomach aches, having loose bowels, and getting an infection.
Irinotecan Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Irinotecan Hydrochloride?
1157 active studies are examining the potential of Irinotecan Hydrochloride to treat Esophageal Cancer, Glioblastoma and Metastatic Colorectal Carcinoma.Condition
Clinical Trials
Trial Phases
Ovarian Cancer
224 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1
Colorectal Carcinoma
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Sarcoma
1 Actively Recruiting
Phase 2
Stomach Cancer
124 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
Pancreatic Cancer
227 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Glioblastoma
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Early Phase 1, Not Applicable
Metastatic Colorectal Carcinoma
25 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Non-Small Cell Lung Cancer
348 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Rhabdomyosarcomas
0 Actively Recruiting
Small Cell Lung Cancer
57 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1
Irinotecan Hydrochloride Reviews: What are patients saying about Irinotecan Hydrochloride?
1Patient Review
2/17/2009 My mother experienced severe negative side effects from this drug, including diarrhea and hair loss. She was hospitalized for two weeks as a result.
Patient Q&A Section about irinotecan hydrochloride
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are indications for irinotecan HCL?
"Irinotecan Hydrochloride medac can be used in combination with 5-fluorouracil, folinic acid, and bevacizumab to treat metastatic colon or rectal cancer."
Answered by AI
Is irinotecan a chemotherapy drug?
"Irinotecan is a chemotherapy drug used to treat cancer, typically bowel cancer. It is also known by its brand name Campto."
Answered by AI
What is the mechanism of action of irinotecan?
"Irinotecan inhibits topoisomerase I from performing its natural function. Without topoisomerase I, the DNA strand cannot be properly religated. This interferes with the moving replication fork, and causes replicative arrest and double-stranded DNA breaks, which are lethal."
Answered by AI
What is irinotecan used for?
"Irinotecan injection is given alongside other medication (for example, 5-fluorouracil, leucovorin) to treat patients with metastatic cancer (a cancer that has already spread) of the colon or rectum."
Answered by AI